Please assess the completion status of the following clinical trial:

Trial Title: Biomarkers in Predicting Response in Patients With Graft-Versus-Host Disease Undergoing Extracorporeal Photophoresis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with any NIH subtype of chronic GVHD that is being treated with ECP~* Karnofsky Performance Scale (KPS) \> 60% at time of study enrollment~* Life expectancy \> 3 months~* Steroid dose not greater than 2 mg/kg prednisone equivalent at time of study enrollment~* If patient has steroid refractory GVHD (defined as worsening of GVHD after 3 days of 2 mg/kg prednisone equivalent or no improvement after 7 days of 2 mg/kg prednisone equivalent), time interval from start of steroids to initiation of ECP should not be \> 14 days~* No use of an investigational agent within 2 weeks of starting ECP~* No uncontrolled bacterial, fungal or viral disease (therapy for cytomegalovirus \[CMV\] viremia is permitted)~* No evidence of relapse or progression of underlying disease (molecular evidence of relapse/progression or mixed chimerism is permitted)~* Women of childbearing potential (WOCBP) should be willing to use 2 forms of contraception; male patients should be willing to use contraception~* Voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the subject at any time without prejudice to future medical care~Exclusion Criteria:~* Female patients who are breastfeeding or pregnant~* Patients known to be human immunodeficiency virus (HIV) positive~* Bronchiolitis obliterans as the sole indication of ECP~* Serious medical or psychiatric illness likely to interfere with participation in this clinical study~* Mechanical ventilation, renal replacement therapy, admitted in intensive care until at time of enrollment~* Stage 4 gastrointestinal GVHD as per Seattle-Glucksberg criteria

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Treg predictor of response to ECP) (Type: EXPERIMENTAL): Patients undergo ECP twice a week for 4 weeks and then twice a week every 2 weeks for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).